Prébonnaud N, Chauzy A, Grégoire N, Dahyot-Fizelier C, Adier C, Marchand S, Aranzana-Climent V
Université de Poitiers, Inserm U1070, PHAR2, Poitiers, France.
Laboratoire de Toxicologie-Pharmacocinétique, CHU de Poitiers, Poitiers, France.
Microbiol Spectr. 2025 Jun 3;13(6):e0005125. doi: 10.1128/spectrum.00051-25. Epub 2025 May 15.
The main objective of this study was to validate an algorithm and experimental setup to simulate first-order absorption pharmacokinetic profiles without altering the standard hollow-fiber infection model (HFIM). For that, clinical cerebrospinal fluid (CSF) linezolid concentrations after 30 min infusions at dosing regimens 600 mg q12 h, 900 mg q12 h, and 900 mg q8 h were reproduced in the HFIM over 4 days. To approximate the apparent first-order absorption observed on CSF pharmacokinetic profiles, we split the dosing interval into a series of sub-intervals during which continuous infusions were delivered to the system. During each sub-interval, the same amount of linezolid was delivered, but the sub-intervals had different durations and flow rates, which were computed by a newly developed algorithm. In addition, we independently reproduced plasma concentrations to validate our system. Samples were collected from the central reservoir and the extracapillary space (ECS) of the cartridge of the HFIM and assayed by liquid chromatography-tandem mass spectrometry. Observed pharmacokinetic parameters and concentrations in the ECS were compared with the target clinical pharmacokinetic parameters and concentrations. Observed pharmacokinetic parameters were within 20% of target pharmacokinetic parameters for all experiments, thus validating the ability of our experimental setup to reproduce plasma and CSF linezolid pharmacokinetic profiles. The algorithm and setup are available in the open-source web application (https://varacli.shinyapps.io/hollow_fiber_app/) to easily design other HFIM experiments.IMPORTANCEWe developed and validated a novel hollow-fiber setup that enables simulation of mono-compartmental pharmacokinetics with an absorption phase. This novel experimental setup was easily implemented on top of the traditional one since it only requires the addition of a programmable infusion pump. Using this streamlined approach, we successfully replicated pharmacokinetics at the infection site, specifically cerebrospinal fluid concentrations of linezolid, consistent with those observed in intensive care unit patients. Thus, this study addresses the challenge of accurately reproducing target site concentrations, rather than relying solely on plasma levels, offering a valuable tool for optimizing dosing regimens in antibiotic therapy. Importantly, this setup also allows for the reproduction of plasma pharmacokinetics following oral (or any other extravascular) administration, broadening its applicability. The algorithm and setup developed in this study were incorporated into an open-source web application designed to facilitate the design of hollow-fiber experimental protocols (https://varacli.shinyapps.io/hollow_fiber_app/).
本研究的主要目的是验证一种算法和实验设置,以模拟一级吸收药代动力学特征,同时不改变标准的中空纤维感染模型(HFIM)。为此,在4天内,通过HFIM重现了给药方案为600mg q12h、900mg q12h和900mg q8h的30分钟输注后临床脑脊液(CSF)中的利奈唑胺浓度。为了近似脑脊液药代动力学特征中观察到的表观一级吸收,我们将给药间隔划分为一系列子间隔,在此期间向系统持续输注药物。在每个子间隔内,输注的利奈唑胺量相同,但子间隔的持续时间和流速不同,这些是通过一种新开发的算法计算得出的。此外,我们独立重现血浆浓度以验证我们的系统。从HFIM药盒的中央储液器和毛细血管外空间(ECS)采集样本,并通过液相色谱 - 串联质谱法进行分析。将在ECS中观察到的药代动力学参数和浓度与目标临床药代动力学参数和浓度进行比较。在所有实验中,观察到的药代动力学参数在目标药代动力学参数的20%以内,从而验证了我们的实验设置重现血浆和脑脊液中利奈唑胺药代动力学特征的能力。该算法和设置可在开源网络应用程序(https://varacli.shinyapps.io/hollow_fiber_app/)中获取,以便轻松设计其他HFIM实验。
重要性
我们开发并验证了一种新型中空纤维设置,能够模拟具有吸收相的单室药代动力学。这种新型实验设置很容易在传统设置的基础上实现,因为它只需要添加一个可编程输液泵。使用这种简化方法,我们成功地在感染部位重现了药代动力学,特别是利奈唑胺的脑脊液浓度,与重症监护病房患者中观察到的浓度一致。因此,本研究解决了准确重现靶部位浓度的挑战,而不是仅仅依赖血浆水平,为优化抗生素治疗的给药方案提供了一个有价值的工具。重要的是,这种设置还允许重现口服(或任何其他血管外)给药后的血浆药代动力学,拓宽了其适用性。本研究中开发的算法和设置被纳入一个开源网络应用程序,旨在促进中空纤维实验方案的设计(https://varacli.shinyapps.io/hollow_fiber_app/)。